Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-interventional, Multicentric, Prospective, Observational Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting

NCT07583485 is registered in ClinicalTrials.gov with Fondazione Oncotech as lead sponsor.

NCT NCT07583485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-interventional, Multicentric, Prospective, Observational Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting
Lead sponsor
Fondazione Oncotech
Phase
Observational
Overall status
Recruiting
Start date
July 1, 2024
Completion date
July 31, 2029
Enrollment
300 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer